Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $6.22 and last traded at $6.40, with a volume of 11231 shares trading hands. The stock had previously closed at $6.44.
A number of brokerages have recently issued reports on ADMS. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies set a $23.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. HC Wainwright set a $40.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. Finally, Northland Securities reissued a “buy” rating and issued a $28.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, March 5th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company’s stock. Adamas Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $23.88.
The stock has a market cap of $175.41 million, a P/E ratio of -1.32 and a beta of 1.43. The company has a debt-to-equity ratio of 1.31, a current ratio of 9.41 and a quick ratio of 9.20.
In related news, CEO Gregory T. Went sold 6,319 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total value of $50,488.81. Following the completion of the sale, the chief executive officer now directly owns 176,291 shares of the company’s stock, valued at approximately $1,408,565.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 8,361 shares of company stock valued at $66,816 over the last ninety days. 24.60% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the stock. First Mercantile Trust Co. increased its position in Adamas Pharmaceuticals by 43.2% in the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 1,740 shares in the last quarter. Advisor Group Inc. increased its position in Adamas Pharmaceuticals by 252.0% in the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 4,510 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Adamas Pharmaceuticals in the 3rd quarter valued at about $104,000. Barclays PLC increased its position in Adamas Pharmaceuticals by 87.6% in the 4th quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 8,118 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Adamas Pharmaceuticals in the 4th quarter valued at about $161,000. 88.28% of the stock is owned by institutional investors and hedge funds.
Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.